After graduating from the Victoria University of Manchester Peter first worked for Boots Pharmaceuticals. He then moved into technical sales with Orme Scientific, Manchester where he established their external sales office in the South East of England. Later  he established the UK division of the PCR instrument manufacturer, Biometra Gmbh, Goettingen, Germany. He managed this operation and then coordinated the subsequent sale of the company into Whatman plc , Maidstone, UK. The successful integration of the business into the plc coupled with other biotech acquisitions during his tenure helped double the share price of the plc and moved the company away from its paper making roots and firmly established them in the biotech sector. He was then approached by the genomics company MWG-Biotech, Munich, Germany to establish their facility in Milton Keynes, UK. He grew the business from $zero to $20M in 3 years and was subsequently invited to join the Main Board in Munich. Some years later he returned to the UK as one of the founders of the London Technology Network, a joint venture between London Business School and London universities. One succesful spin off from this was Peter’s next challenge; the establishment of the first UK Korean genomics company and it's sister DNA production facility in Alameda, USA.This vast experience is now being chanelled into his next step as the COO of MP Sciences, a company that will be the major portal for the latest genomic and proteomic technologies.Peter is a member of the Royal Pharmaceutical Society of Great Britain, a board member of Milton Partnerships, a member of the British Proteomics Society Executive committee, the Institute of Directors and advisor to several Health Authority Patient advisory groups.

Contact Peter